A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Heparin Anti-Xa, Plasma
Test CodeAlias/See Also
Anti-10a
Anti-Xa
Fragmin (Dalteparin)
Heparin Anti-Xa Assay, Plasma
Lovenox (Enoxaparin)
Low-Molecular Weight Heparin Assay
Unfractionated Heparin Assay
Preferred Specimen
Collection Container/Tube: Light-blue top (3.2% sodium citrate)
Submission Container/Tube: Plastic vial
Specimen Volume: 1 mL
Minimum Volume
Instructions
Collection Instructions: Spin down, remove plasma and spin plasma again
Additional Information: Double-centrifuged specimen is critical for accurate results as platelet contamination may cause spurious results.
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Hemolysis | Mild OK; Gross Reject |
Lipemia | Mild OK |
Icterus | Mild OK |
Other | Insufficiently filled tube |
Methodology
Chromogenic
Reference Range
Check enoxaparin troughs for safety monitoring
Peak Monitoring:
Peaks not recommended for prophylactic dosing, only for therapeutic dosing
Check peak anti Xa levels 3-4 hours after a dose.
Expected peak anti Xa levels for q12h dosing = 0.5 – 1 units/ml
Expected peak anti Xa levels for q24h dosing = 1-2 units/ml
Trough Monitoring:
Check trough anti Xa levels immediately prior to the next dose
Expected trough anti Xa levels = < 0.5 units/ml
Higher troughs suggest impaired clearance
Clinical Significance
Measuring heparin concentration:
-In patients treated with low-molecular-weight heparin preparations
-In the presence of prolonged baseline activated partial thromboplastin time (APTT) (eg, lupus anticoagulant, "contact factor" deficiency, etc)
-When unfractionated heparin dose needed to achieve desired APTT prolongation is unexpectedly higher (>50%) than expected
Not useful for monitoring therapy with the heparinoid "danaparoid"
Performed By
CoxHealth
Performing Laboratory
CoxHealth